Oseltamivir is the most widely used antiviral choices regarding influenza medication for its potent inhibitor of influenza virus neuraminidase (NA) protein. But, it was first reported on January 2008 that a number of influenza A viruses (H1N1) with resistance to oseltamivir has been increasing in transmission numbers (WHO). The following article will provide you with informations about the widespread transmission of Oseltamivir Resistance Influenza A Viruses (H1N1) in association with its morbidity and mortality.

These oseltamivir-resistant influenza A(H1N1) viruses contained a specific genetic mutation in the NA protein structure (H274Y/H275Y). Accordingly, these viruses presumed to exhibit attenuated pathogenicity, compromised transmission, and reduced lethality. But the widespread suggests that these viruses retain significant transmissibility and pathogenicity.

Within the article you will find sections such Clinical Characteristics of Hospitalized Patients With Oseltamivir-Resistant Influenza A(H1N1) Virus Infection, Epidemic Curve of Onset of Symptoms and Timeline of Influenza A(H1N1) Nosocomial Infections, and Phylogenetic Relationship of Nosocomial Patient Cluster Influenza A(H1N1) Viruses and Other 2007-2008 Seasonal Influenza A Viruses.

Please complete read of The Transmission of Oseltamivir-Resistant Influenza A(H1N1) Viruses in this article of pdf filetype (source: jama.ama-assn.org)